Temperature Dysregulation with Vraylar
Yes, temperature dysregulation is a recognized side effect of Vraylar (cariprazine), though it occurs infrequently. The FDA label explicitly warns that atypical antipsychotics like Vraylar may disrupt the body's ability to reduce core body temperature 1.
Mechanism and Risk Factors
Atypical antipsychotics disrupt the body's thermoregulatory mechanisms, affecting the hypothalamus's ability to maintain normal core temperature 1. This is distinct from neuroleptic malignant syndrome (NMS), which is a rare but life-threatening condition characterized by fever, muscle rigidity, altered mental status, and autonomic instability 2.
Conditions That Increase Risk
You should use Vraylar with caution if the patient experiences 1:
- Strenuous exercise
- Exposure to extreme heat
- Dehydration
- Concurrent anticholinergic medications (which further impair heat dissipation)
Clinical Presentation
Temperature dysregulation with Vraylar typically manifests as 1:
- Difficulty tolerating heat
- Impaired sweating response
- Elevated core body temperature in hot environments
- Feeling excessively warm without appropriate environmental triggers
This is different from drug-induced fever, which presents as persistent elevation in temperature and typically occurs days to weeks after starting medication (mean 21 days, median 8 days) 2.
Distinguishing from Neuroleptic Malignant Syndrome
You must rule out NMS if temperature elevation is accompanied by 2, 1:
- High fever (often >41°C)
- Muscle rigidity or hypertonicity
- Altered mental status or confusion
- Autonomic instability (tachycardia, blood pressure fluctuations, diaphoresis, pallor)
- Elevated creatine phosphokinase levels
NMS occurs in 0.02-3% of patients on antipsychotics and requires immediate discontinuation of the medication and emergency treatment 2.
Management Approach
For Simple Temperature Dysregulation:
Counsel patients to 1:
- Avoid prolonged exposure to extreme heat
- Stay well-hydrated, especially during warm weather
- Limit strenuous physical activity in hot environments
- Recognize early warning signs (excessive warmth, reduced sweating)
For Suspected NMS:
Immediately discontinue Vraylar and seek emergency care if the patient develops the tetrad of fever, rigidity, altered mental status, and autonomic dysfunction 2, 1. Treatment includes supportive care, cooling measures, and potentially dantrolene or bromocriptine, though evidence for these agents is limited 2.
Important Caveats
Cariprazine has a very long half-life (2-5 days for parent drug, even longer for active metabolites), meaning side effects can emerge weeks after starting treatment or dose increases, and may persist for weeks after discontinuation 1, 3. The FDA label specifically warns about "late occurring adverse reactions" that may not appear immediately 1.
Temperature dysregulation is generally manageable with appropriate precautions and does not typically require discontinuation of Vraylar unless it progresses to NMS or causes significant functional impairment 1. However, elderly patients, those with cardiovascular disease, and those on multiple medications warrant closer monitoring 1.